1. Home
  2. OKYO
  3. OKYO News

Latest OKYO Pharma Limited (OKYO) News on August 25, 2025

OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders
OKYO

Simply Wall St.

2 months ago

OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders

OKYO

ACCESS Newswire

2 months ago

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

OKYO Pharma to Present at the Bio International Convention
OKYO

GlobeNewswire

2 months ago

OKYO Pharma to Present at the Bio International Convention

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
OKYO

GlobeNewswire

3 months ago

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
OKYO

GlobeNewswire

4 months ago

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
OKYO

GlobeNewswire

4 months ago

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
OKYO

GlobeNewswire

5 months ago

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
OKYO

GlobeNewswire

6 months ago

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
OKYO

GlobeNewswire

6 months ago

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares
OKYO

GlobeNewswire

7 months ago

OKYO Pharma Announces Chairman and CEO Acquire Shares

OKYO

ACCESS Newswire

7 months ago

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
OKYO

GlobeNewswire

7 months ago

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

Okyo Pharma receives $1.4M in non-dilutive financing
OKYO

TipRanks

7 months ago

Okyo Pharma receives $1.4M in non-dilutive financing

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
OKYO

GlobeNewswire

7 months ago

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference
OKYO

GlobeNewswire

9 months ago

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
OKYO

ACCESSWIRE

9 months ago

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
OKYO

GlobeNewswire

10 months ago

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
OKYO

GlobeNewswire

10 months ago

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug
OKYO

TipRanks

10 months ago

OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
OKYO

GlobeNewswire

10 months ago

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Announces Chairman Acquires Shares
OKYO

GlobeNewswire

a year ago

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Announces Chairman Acquires Shares
OKYO

GlobeNewswire

a year ago

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
OKYO

GlobeNewswire

a year ago

OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
OKYO

ACCESSWIRE

a year ago

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OKYO Pharma CEO Interview to Air on Bloomberg TV
OKYO

GlobeNewswire

a year ago

OKYO Pharma CEO Interview to Air on Bloomberg TV

OKYO

MT Newswires

a year ago

OKYO Pharma Rises Pre-Bell on Chairman's Acquisition of Additional Shares

OKYO Pharma Announces Chairman Acquires Shares
OKYO

GlobeNewswire

a year ago

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Announces Chairman Acquires Shares
OKYO

GlobeNewswire

a year ago

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
OKYO

GlobeNewswire

a year ago

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
OKYO

GlobeNewswire

a year ago

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
OKYO

GlobeNewswire

a year ago

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
OKYO

GlobeNewswire

a year ago

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

OKYO Pharma Announces Participation in May 2024 Investor Conferences
OKYO

GlobeNewswire

a year ago

OKYO Pharma Announces Participation in May 2024 Investor Conferences

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
OKYO

GlobeNewswire

a year ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
OKYO

GlobeNewswire

a year ago

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
OKYO

GlobeNewswire

a year ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
OKYO

GlobeNewswire

a year ago

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
OKYO

GlobeNewswire

a year ago

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
OKYO

GlobeNewswire

a year ago

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
OKYO

GlobeNewswire

2 years ago

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
OKYO

GlobeNewswire

2 years ago

OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board

15 Cash-Rich Penny Stocks Hedge Funds Are Buying
OKYO

Insider Monkey

2 years ago

15 Cash-Rich Penny Stocks Hedge Funds Are Buying

ISG to Publish Reports on Google Cloud Ecosystem
OKYO

Business Wire

2 years ago

ISG to Publish Reports on Google Cloud Ecosystem

OP Bancorp Reports Steady Earnings Amidst Economic Headwinds
OKYO

GuruFocus.com

2 years ago

OP Bancorp Reports Steady Earnings Amidst Economic Headwinds

OKYO

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 01/25/2024

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
OKYO

Newsfile

2 years ago

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

OKYO

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 01/24/2024

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
OKYO

PR Newswire

2 years ago

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

LifeMD to Participate in the Maxim Group 2024 Healthcare IT Virtual Conference
OKYO

GlobeNewswire

2 years ago

LifeMD to Participate in the Maxim Group 2024 Healthcare IT Virtual Conference

Analyst Approved: 3 Stocks Wall Street Insiders Are Whispering About
OKYO

InvestorPlace

2 years ago

Analyst Approved: 3 Stocks Wall Street Insiders Are Whispering About

OKYO

Reuters

2 years ago

Emergent extends shelf life of opioid overdose reversal drug Narcan

Mage Networks Signs Memorandum of Understanding for Telesat Lightspeed Services
OKYO

GlobeNewswire

2 years ago

Mage Networks Signs Memorandum of Understanding for Telesat Lightspeed Services

Bluerock Homes Trust (BHM) Announces First Quarter Dividends on Series A Preferred Stock
OKYO

PR Newswire

2 years ago

Bluerock Homes Trust (BHM) Announces First Quarter Dividends on Series A Preferred Stock

Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
OKYO

Zacks

2 years ago

Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine

Five Point Holdings, LLC Sets Date for Fourth Quarter and Year-end 2023 Earnings Announcement and Investor Conference Call
OKYO

Business Wire

2 years ago

Five Point Holdings, LLC Sets Date for Fourth Quarter and Year-end 2023 Earnings Announcement and Investor Conference Call

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
OKYO

GlobeNewswire

2 years ago

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to February 9, 2024
OKYO

GlobeNewswire

2 years ago

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to February 9, 2024

Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
OKYO

GlobeNewswire

2 years ago

Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
OKYO

GlobeNewswire

2 years ago

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
OKYO

GlobeNewswire

2 years ago

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3
OKYO

NewMediaWire

2 years ago

Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3

Are Oils-Energy Stocks Lagging CrossAmerica Partners (CAPL) This Year?
OKYO

Zacks

2 years ago

Are Oils-Energy Stocks Lagging CrossAmerica Partners (CAPL) This Year?

NorthEast Community Bancorp Inc's Dividend Analysis
OKYO

GuruFocus.com

2 years ago

NorthEast Community Bancorp Inc's Dividend Analysis

Independent Chairman of the Board of Vivani Medical Gregg Williams Buys 1.2% More Shares
OKYO

Simply Wall St.

2 years ago

Independent Chairman of the Board of Vivani Medical Gregg Williams Buys 1.2% More Shares

Clene Announces New Data from HEALEY ALS Platform Trial
OKYO

NewMediaWire

2 years ago

Clene Announces New Data from HEALEY ALS Platform Trial

Capricor Therapeutics (NASDAQ:CAPR) shareholders are up 16% this past week, but still in the red over the last five years
OKYO

Simply Wall St.

2 years ago

Capricor Therapeutics (NASDAQ:CAPR) shareholders are up 16% this past week, but still in the red over the last five years

Billionaire Lee Cooperman’s 10 Stock Picks with Huge Upside Potential
OKYO

Insider Monkey

2 years ago

Billionaire Lee Cooperman’s 10 Stock Picks with Huge Upside Potential

OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
OKYO

GlobeNewswire

2 years ago

OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
OKYO

GlobeNewswire

2 years ago

Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer

Is Vivani Medical (NASDAQ:VANI) In A Good Position To Invest In Growth?
OKYO

Simply Wall St.

2 years ago

Is Vivani Medical (NASDAQ:VANI) In A Good Position To Invest In Growth?

Regional Management (NYSE:RM) Could Be A Buy For Its Upcoming Dividend
OKYO

Simply Wall St.

2 years ago

Regional Management (NYSE:RM) Could Be A Buy For Its Upcoming Dividend

Gabelli Convertible and Income Securities Fund Declares Fourth Quarter Distribution of $0.12 per Share
OKYO

GlobeNewswire

2 years ago

Gabelli Convertible and Income Securities Fund Declares Fourth Quarter Distribution of $0.12 per Share

OKYO

GuruFocus.com

2 years ago

Fonar Corp (FONR) Reports Substantial Growth in Q1 Fiscal 2024 Earnings

Polestar 4 production starts; first customer deliveries expected before end of 2023
OKYO

Business Wire

2 years ago

Polestar 4 production starts; first customer deliveries expected before end of 2023

OKYO

Associated Press Finance

2 years ago

Fonar: Fiscal Q1 Earnings Snapshot

Fonar Announces Financial Results for the 1st Quarter of Fiscal 2024
OKYO

Newsfile

2 years ago

Fonar Announces Financial Results for the 1st Quarter of Fiscal 2024

Need To Know: Analysts Just Made A Substantial Cut To Their Clarus Corporation (NASDAQ:CLAR) Estimates
OKYO

Simply Wall St.

2 years ago

Need To Know: Analysts Just Made A Substantial Cut To Their Clarus Corporation (NASDAQ:CLAR) Estimates

Grosvenor Capital Management's (NASDAQ:GCMG) Dividend Will Be $0.11
OKYO

Simply Wall St.

2 years ago

Grosvenor Capital Management's (NASDAQ:GCMG) Dividend Will Be $0.11

KORE Reports Third Quarter 2023 Results: Announces Successful Refinancing and Preferred Stock Issuance Transactions
OKYO

PR Newswire

2 years ago

KORE Reports Third Quarter 2023 Results: Announces Successful Refinancing and Preferred Stock Issuance Transactions

Full House Resorts Announces Strong Third Quarter Results
OKYO

GlobeNewswire

2 years ago

Full House Resorts Announces Strong Third Quarter Results

Fonar Announces Distributor Agreement with AIRS Medical, Leader in AI-Powered MRI Technology
OKYO

Newsfile

2 years ago

Fonar Announces Distributor Agreement with AIRS Medical, Leader in AI-Powered MRI Technology

GCM Grosvenor Reports Third Quarter 2023 Earnings Results
OKYO

GlobeNewswire

2 years ago

GCM Grosvenor Reports Third Quarter 2023 Earnings Results

Finance of America Reports Third Quarter 2023 Results
OKYO

Business Wire

2 years ago

Finance of America Reports Third Quarter 2023 Results

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023
OKYO

GlobeNewswire

2 years ago

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023

OKYO

GuruFocus.com

2 years ago

United Bancorp Inc (UBCP) Reports Increased Earnings for Q3 and First Nine Months of 2023

United Bancorp, Inc. Reports Increased 2023 Third Quarter and Nine Month Earnings Results
OKYO

ACCESSWIRE

2 years ago

United Bancorp, Inc. Reports Increased 2023 Third Quarter and Nine Month Earnings Results

GCM Grosvenor Customized Infrastructure Strategies III Fund Holds Final Close as Firm Continues to See Strong Demand for Infrastructure Investments
OKYO

GlobeNewswire

2 years ago

GCM Grosvenor Customized Infrastructure Strategies III Fund Holds Final Close as Firm Continues to See Strong Demand for Infrastructure Investments

Share on Social Networks: